BCRX
BioCryst Pharmaceuticals, Inc.
BCRX lost money over the past year, so it has no meaningful PE right now. Analysts expect earnings to recover and profitability to improve, though they disagree widely on how much.
BCRX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Strong | |
| Strong |
BCRX's revenue, cash flow and balance sheet are currently healthy, but its profitability is weak.
BCRX PE Valuation
BCRX has no meaningful PE right now: it lost money over the past year.
BCRX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for BCRX, with profitability improving. However, they disagree widely on these estimates.
BCRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.66 | — |
| Q3 2026 | -$1.41 | -$1.36 |
| Q2 2026 | -$1.49 | -$1.31 |
| Q1 2026 | -$1.77 | -$1.51 |
| Q4 2025 | $1.21 | +$1.64 |
| Q3 2025 | -$0.05 | +$0.56 |
| Q2 2025 | -$0.18 | +$0.55 |
| Q1 2025 | -$0.26 | +$0.81 |
| Q4 2024 | -$0.43 | +$0.75 |
BCRX lost $1.41 per share over the past year, a bigger loss than the year before.
BCRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $180.3M | +13% |
| Q2 2026 | $218.3M | +34% |
| Q1 2026 | $156.4M | +7.5% |
| Q4 2025 | $406.6M | +209% |
| Q3 2025 | $159.4M | +36% |
| Q2 2025 | $163.4M | +49% |
| Q1 2025 | $145.5M | +57% |
| Q4 2024 | $131.5M | +41% |
BCRX's revenue has grown year over year for 23 quarters in a row: $180M last quarter, up 13% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | +11 points |
| Q2 2026 | 45% | +27 points |
| Q1 2026 | -449% | -463 points |
| Q4 2025 | 64% | +68 points |
| Q3 2025 | 19% | +12 points |
| Q2 2025 | 18% | +10 points |
| Q1 2025 | 15% | +30 points |
| Q4 2024 | -3.4% | +42 points |
BCRX's operating margin was 30% last quarter, up 11 points from the same quarter a year ago.
BCRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $32.8M | -19% |
| Q2 2026 | $104.1M | +153% |
| Q1 2026 | -$62.2M | -$34.5M |
| Q4 2025 | $291.2M | +$297M |
| Q3 2025 | $40.3M | +392% |
| Q2 2025 | $41.1M | +$42.6M |
| Q1 2025 | -$27.7M | +$26.3M |
| Q4 2024 | -$5.9M | +$3.6M |
BCRX has burned cash in most quarters: $366M over the past year, about eight times what it generated the year before.
BCRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.5M shares |
| 1 year | +22% | +47.7M shares |
| 3 years | +41% | +78M shares |
| 5 years | +51% | +90.3M shares |
| Available history | +74% | +113M shares |
BCRX has 268M diluted shares, up 22% from a year ago.
BCRX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2025 | -0.3x | Net Cash |
| Q3 2025 | 1.4x | Healthy |
| Q2 2025 | 2.8x | Moderate |
| Q1 2025 | 6.1x | High |
BCRX has more cash than debt.
BCRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.7 | Neutral |
| Stochastic | 16.2 | Oversold |
BCRX's weekly RSI is 43 (neutral) and its Stochastic is 16 (oversold).
BCRX PE vs Healthcare Sector
BCRX has no meaningful PE right now: it lost money over the past year.
BCRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $8.07 | 4.8% below |
| 20 week MA | $8.89 | 14% below |
| 50 week MA | $8.50 | 9.6% below |
| 100 week MA | $8.38 | 8.4% below |
| 200 week MA | $7.71 | 0.4% below |
BCRX is in a downtrend: it's below all five of its weekly moving averages, and 0.4% below its 200-week average.
BCRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $3.12 | $7.28 | +133% |
| 2021 | $7.28 | $13.9 | +91% |
| 2022 | $13.9 | $11.5 | -18% |
| 2023 | $11.5 | $5.99 | -48% |
| 2024 | $5.99 | $7.71 | +29% |
| 2025 | $7.71 | $7.63 | -1% |
| 2026 YTD | $7.63 | $7.68 | +0.7% |
BCRX's yearly returns have swung widely, from +133% in 2020 to −48% in 2023. It's up 0.7% so far in 2026.